Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

Functional antibody CDR3 fusion proteins with enhanced pharmacological properties.

Zhang Y, Wang D, de Lichtervelde L, Sun SB, Smider VV, Schultz PG, Wang F.

Angew Chem Int Ed Engl. 2013 Aug 5;52(32):8295-8. doi: 10.1002/anie.201303656. Epub 2013 Jun 21. No abstract available.

2.

Humanization of antibodies using heavy chain complementarity-determining region 3 grafting coupled with in vitro somatic hypermutation.

Bowers PM, Neben TY, Tomlinson GL, Dalton JL, Altobell L, Zhang X, Macomber JL, Wu BF, Toobian RM, McConnell AD, Verdino P, Chau B, Horlick RA, King DJ.

J Biol Chem. 2013 Mar 15;288(11):7688-96. doi: 10.1074/jbc.M112.445502. Epub 2013 Jan 25.

3.

Comment on "Engineering antibody heavy chain CDR3 to create a phage display Fab library rich in antibodies that bind charged carbohydrates".

Lucas AH, Reason DC.

J Immunol. 2009 May 1;182(9):5160-1. doi: 10.4049/jimmunol.0990032. No abstract available.

4.

Functional human antibody CDR fusions as long-acting therapeutic endocrine agonists.

Liu T, Zhang Y, Liu Y, Wang Y, Jia H, Kang M, Luo X, Caballero D, Gonzalez J, Sherwood L, Nunez V, Wang D, Woods A, Schultz PG, Wang F.

Proc Natl Acad Sci U S A. 2015 Feb 3;112(5):1356-61. doi: 10.1073/pnas.1423668112. Epub 2015 Jan 20.

6.

Grafting of "abbreviated" complementarity-determining regions containing specificity-determining residues essential for ligand contact to engineer a less immunogenic humanized monoclonal antibody.

De Pascalis R, Iwahashi M, Tamura M, Padlan EA, Gonzales NR, Santos AD, Giuliano M, Schuck P, Schlom J, Kashmiri SV.

J Immunol. 2002 Sep 15;169(6):3076-84.

7.

The critical role of arginine residues in the binding of human monoclonal antibodies to cardiolipin.

Giles I, Lambrianides N, Latchman D, Chen P, Chukwuocha R, Isenberg D, Rahman A.

Arthritis Res Ther. 2005;7(1):R47-56. Epub 2004 Nov 16.

8.

Use of human germline genes in a CDR homology-based approach to antibody humanization.

Hwang WY, Almagro JC, Buss TN, Tan P, Foote J.

Methods. 2005 May;36(1):35-42.

PMID:
15848073
9.

Aggregation-resistant domain antibodies engineered with charged mutations near the edges of the complementarity-determining regions.

Perchiacca JM, Ladiwala AR, Bhattacharya M, Tessier PM.

Protein Eng Des Sel. 2012 Oct;25(10):591-601. Epub 2012 Jul 27.

PMID:
22843678
10.

Rational design of CXCR4 specific antibodies with elongated CDRs.

Liu T, Liu Y, Wang Y, Hull M, Schultz PG, Wang F.

J Am Chem Soc. 2014 Jul 30;136(30):10557-60. doi: 10.1021/ja5042447. Epub 2014 Jul 18.

11.

Antibody humanization methods - a review and update.

Safdari Y, Farajnia S, Asgharzadeh M, Khalili M.

Biotechnol Genet Eng Rev. 2013;29:175-86. doi: 10.1080/02648725.2013.801235. Epub 2013 Aug 2. Review.

PMID:
24568279
12.

Humanization of a murine monoclonal antibody by simultaneous optimization of framework and CDR residues.

Wu H, Nie Y, Huse WD, Watkins JD.

J Mol Biol. 1999 Nov 19;294(1):151-62.

PMID:
10556035
13.

A general approach to antibody thermostabilization.

McConnell AD, Zhang X, Macomber JL, Chau B, Sheffer JC, Rahmanian S, Hare E, Spasojevic V, Horlick RA, King DJ, Bowers PM.

MAbs. 2014;6(5):1274-82. doi: 10.4161/mabs.29680.

14.

Affinity maturation of a humanized rat antibody for anti-RAGE therapy: comprehensive mutagenesis reveals a high level of mutational plasticity both inside and outside the complementarity-determining regions.

Finlay WJ, Cunningham O, Lambert MA, Darmanin-Sheehan A, Liu X, Fennell BJ, Mahon CM, Cummins E, Wade JM, O'Sullivan CM, Tan XY, Piche N, Pittman DD, Paulsen J, Tchistiakova L, Kodangattil S, Gill D, Hufton SE.

J Mol Biol. 2009 May 8;388(3):541-58. doi: 10.1016/j.jmb.2009.03.019. Epub 2009 Mar 13.

PMID:
19285987
15.

Affinity maturation of a novel antagonistic human monoclonal antibody with a long VH CDR3 targeting the Class A GPCR formyl-peptide receptor 1.

Douthwaite JA, Sridharan S, Huntington C, Hammersley J, Marwood R, Hakulinen JK, Ek M, Sjögren T, Rider D, Privezentzev C, Seaman JC, Cariuk P, Knights V, Young J, Wilkinson T, Sleeman M, Finch DK, Lowe DC, Vaughan TJ.

MAbs. 2015;7(1):152-66. doi: 10.4161/19420862.2014.985158.

16.

SDR grafting--a new approach to antibody humanization.

Kashmiri SV, De Pascalis R, Gonzales NR, Schlom J.

Methods. 2005 May;36(1):25-34. Review.

PMID:
15848072
17.

Fundamental characteristics of the expressed immunoglobulin VH and VL repertoire in different canine breeds in comparison with those of humans and mice.

Steiniger SC, Dunkle WE, Bammert GF, Wilson TL, Krishnan A, Dunham SA, Ippolito GC, Bainbridge G.

Mol Immunol. 2014 May;59(1):71-8. doi: 10.1016/j.molimm.2014.01.010. Epub 2014 Feb 4.

PMID:
24509215
18.

Stability and CDR composition biases enrich binder functionality landscapes.

Hackel BJ, Ackerman ME, Howland SW, Wittrup KD.

J Mol Biol. 2010 Aug 6;401(1):84-96. doi: 10.1016/j.jmb.2010.06.004. Epub 2010 Jun 9.

19.

High-throughput generation of synthetic antibodies from highly functional minimalist phage-displayed libraries.

Fellouse FA, Esaki K, Birtalan S, Raptis D, Cancasci VJ, Koide A, Jhurani P, Vasser M, Wiesmann C, Kossiakoff AA, Koide S, Sidhu SS.

J Mol Biol. 2007 Nov 2;373(4):924-40. Epub 2007 Aug 19.

PMID:
17825836
20.

Balancing charge in the complementarity-determining regions of humanized mAbs without affecting pI reduces non-specific binding and improves the pharmacokinetics.

Datta-Mannan A, Thangaraju A, Leung D, Tang Y, Witcher DR, Lu J, Wroblewski VJ.

MAbs. 2015;7(3):483-93. doi: 10.1080/19420862.2015.1016696.

Supplemental Content

Support Center